Livforsakringsbolaget Skandia Omsesidigt Has $9.90 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6,925.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,100 shares of the biotechnology company’s stock after purchasing an additional 27,700 shares during the period. Livforsakringsbolaget Skandia Omsesidigt owned 0.06% of United Therapeutics worth $9,904,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. USA Financial Formulas acquired a new position in United Therapeutics in the third quarter valued at $33,000. Brooklyn Investment Group acquired a new position in United Therapeutics in the third quarter valued at $33,000. Capital Performance Advisors LLP acquired a new position in United Therapeutics in the third quarter valued at $82,000. MassMutual Private Wealth & Trust FSB lifted its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the period. Finally, Values First Advisors Inc. acquired a new position in United Therapeutics in the third quarter valued at $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent analyst reports. UBS Group boosted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. LADENBURG THALM/SH SH boosted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Argus lifted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $353.75 on Friday. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $417.82. The company has a 50-day simple moving average of $363.31 and a two-hundred day simple moving average of $357.63. The company has a market capitalization of $15.79 billion, a price-to-earnings ratio of 15.54, a PEG ratio of 0.92 and a beta of 0.57.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $353.64, for a total transaction of $3,536,400.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $911,330.28. This represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 128,614 shares of company stock valued at $47,868,005. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.